PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 10860094

Erectile dysfunction, sildenafil and cardiovascular risk.

K K Chew·B G Stuckey·P L Thompson
View original source ↗Export metadata ↓

Abstract

Cardiovascular risk factors are commonly associated with erectile dysfunction and should be identified and treated. Patients with cardiovascular diseases should be assessed and counselled regarding their fitness for sexual activity. The danger of concurrent use of sildenafil and nitrates under any circumstances, regardless of age and sex, must be highlighted at all levels of the community. Sildenafil is absolutely contraindicated in patients receiving treatment with long-acting nitrates for ischaemic heart disease. Patients who need sublingual short-acting nitrates infrequently should not be precluded from taking sildenafil, provided they are aware that sildenafil is not to be taken within 24 h of taking the nitrate.

Explore related subjects

3',5'-Cyclic-GMP PhosphodiesterasesAlgorithmsCardiovascular DiseasesCoitusErectile DysfunctionHumansMalePhosphodiesterase InhibitorsPiperazinesPurinesSildenafil CitrateSulfonesJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

K K Chew, B G Stuckey, P L Thompson. 2000-03-20. Erectile dysfunction, sildenafil and cardiovascular risk.. https://pubmed.ncbi.nlm.nih.gov/10860094/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Phosphorylation of phosphodiesterase-5 is promoted by a conformational change induced by sildenafil, vardenafil, or tadalafil.

Phosphodiesterase-5 (PDE5) inhibitors (sildenafil, vardenafil, or tadalafil) or phosphorylation by cyclic nucleotide-dependent protein kinase causes an apparent conformational change in PDE5, as indicated by a shift in migration on non-denaturing PAGE gels and an altered pattern of tryptic digestion. Combination of cGMP and a PDE5 inhibitor or phosphorylation does not cause a further gel shift or change in tryptic digest. Phosphorylation of PDE5 is stimulated by inhibitors, and combination of cGMP and inhibitor does not cause further phosphorylation. Dephosphorylation of PDE5 by either purified phosphoprotein phosphatase-1 or -2A catalytic subunit or by a crude phosphatase mixture is not affected by cGMP or inhibitors, suggesting that phosphorylation itself maintains conformational exposure of the phosphorylation site. The combined results imply that cGMP binding to the catalytic site initiates negative feedback control of many cellular cGMP signaling pathways by directly stimulating phosphorylation and activation of PDE5; by exploiting this molecular mechanism, PDE5 inhibitors stimulate their own potencies.

3',5'-Cyclic-GMP Phosphodiesterases↗
PubMed2007

Evaluation and diagnostic testing of erectile dysfunction in the era of phosphodiesterase type 5 inhibitors.

The diagnosis and treatment of erectile dysfunction has changed dramatically since the availability of safe and effective oral therapies. Unfortunately, not all men can be adequately treated in this way, and might require more invasive testing to diagnose and treat the specific cause of their dysfunction. This review looks at the tests and strategies available for men who cannot be treated by oral therapy alone.

3',5'-Cyclic-GMP Phosphodiesterases↗